What is Nitric Oxide? Nitric Oxide (NO) is an endogenous gas that acts as a potent vascular smooth muscle relaxant. In clinical medicine, inhaled Nitric Oxide (iNO) is used as a selective pulmonary vasodilator. Approved by the US FDA in 1999 under the brand name INOmax, it is a life-saving therapy in neonatal intensive care settings for infants suffering from respiratory failure associated with pulmonary hypertension. Administered as a gas mixture via specialized delivery systems, inhaled Nitric Oxide acts locally in the lungs. It dilates blood vessels in ventilated regions of the lungs without causing systemic vasodilation, improving oxygenation and reducing the need for extracorporeal membrane oxygenation (ECMO). Mechanism of Action Nitric oxide is a naturally occurring molecule produced by vascular endothelial cells that regulates vascular tone throughout the body. In the lungs, it is involved in maintaining low pulmonary vascular resistance. Inhaled Nitric Oxide gas diffuses across the alveoli into the adjacent pulmonary vascular smooth muscle cells. Once inside the smooth muscle cells, Nitric Oxide binds to and activates the heme moiety of soluble guanylate cyclase. This enzyme catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). The accumulation of intracellular cGMP activates cGMP-dependent protein kinases, leading to decreased intracellular calcium levels and smooth muscle relaxation. Because Nitric Oxide is inhaled, its vasodilatory effect is selective to the pulmonary circulation. Furthermore, it selectively dilates blood vessels in well-ventilated areas of the lung, where the gas reaches the alveoli. This improves matching of ventilation and perfusion (V/Q matching), redistributes blood flow away from poorly ventilated lung regions toward well-ventilated areas, and decreases pulmonary artery pressure. Once Nitric Oxide enters the bloodstream, it is immediately inactivated by binding to hemoglobin, preventing systemic vasodilation and hypotension. Pharmacokinetics & Elimination The pharmacokinetics of inhaled Nitric Oxide are unique because it acts locally and is rapidly inactivated in the pulmonary capillary bed. Upon diffusing into the bloodstream, Nitric Oxide reacts with oxyhemoglobin to form methemoglobin and nitrate. This reaction occurs within fractions of a second, resulting in a systemic half-life of less than 6 seconds. Methemoglobin is subsequently reduced back to divalent hemoglobin by methemoglobin reductase enzymes within red blood cells. Nitrate is excreted primarily through the kidneys, with more than 70% of the inhaled dose recovered as nitrate in the urine within 48 hours. Because of this rapid inactivation, the pharmacological effects of inhaled Nitric Oxide are localized to the pulmonary vasculature, with no significant systemic hemodynamic effects. Clinical Indications & Dosage Inhaled Nitric Oxide is indicated for the treatment of term and near-term (born at > 34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. It improves oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO). It is also used off-label in adult intensive care for severe acute respiratory distress syndrome (ARDS) and in cardiac surgery to manage acute post-operative pulmonary hypertension. The standard recommended dose of inhaled Nitric Oxide is 20 parts per million (ppm). Doses above 20 ppm are generally not recommended because they do not provide additional clinical benefit and are associated with a higher risk of methemoglobinemia and nitrogen dioxide toxicity. Treatment is typically maintained for up to 14 days or until the underlying pulmonary condition resolves, followed by a gradual weaning process to prevent rebound pulmonary hypertension. Warnings & Safety warnings Inhaled Nitric Oxide requires precise monitoring to avoid toxic complications: Methemoglobinemia: Nitric Oxide combines with hemoglobin to form methemoglobin, which cannot transport oxygen. Methemoglobin levels must be monitored daily. If levels exceed 5%, the dose of Nitric Oxide should be reduced, and if they exceed 7%, treatment may need to be discontinued or treated with intravenous methylene blue. Nitrogen Dioxide (NO2) Toxicity: Nitric Oxide reacts with oxygen to form nitrogen dioxide (NO2), a toxic gas that can cause airway inflammation and pulmonary edema. The delivery system must continuously monitor NO2 levels, keeping them below 1.5 ppm. Rebound Pulmonary Hypertension: Abrupt withdrawal of inhaled Nitric Oxide can cause a rapid increase in pulmonary artery pressure and a severe drop in blood oxygenation. Weaning must be done gradually, under close hemodynamic monitoring. Frequently Asked Questions Why is Nitric Oxide inhaled rather than given intravenously? Inhaling Nitric Oxide delivers the gas directly to the lungs, causing selective dilation of the pulmonary arteries. If given intravenously, it would cause systemic vasodilation, leading to a severe, dangerous drop in blood pressure throughout the body. What is methemoglobinemia? Methemoglobinemia is a condition where too much methemoglobin is formed in the blood. Methemoglobin cannot release oxygen to body tissues, leading to tissue hypoxia. It is monitored via blood gas analysis during Nitric Oxide therapy.